Lutris Pharma Reports Positive Phase 1/2 Results for LUT014 in Breast Cancer Radiation Dermatitis

Lutris Pharma, a biopharmaceutical firm, has published positive results from a phase 1/2 clinical trial of their lead compound, LUT014, which is a topical B-Raf inhibitor. The study focused on treating radiation-induced dermatitis (RD) in breast cancer patients. According to the findings, LUT014 was well-tolerated, with no serious adverse events reported. In the first part of the trial, 75% of patients with grade 2 RD saw a complete resolution of their condition by day 28. The second part of the trial indicated a 30% clinical benefit for LUT014 over a placebo. The compound is believed to have the potential to improve patients' quality of life and accelerate recovery from RD, a condition for which there is currently no standard treatment.
The trial was divided into an open-label phase and a double-blind, placebo-controlled phase. In the open-label phase, all eight patients showed an improvement in their RD condition after 28 days of LUT014 treatment. The double-blind phase involved 20 patients and aimed to assess the efficacy of LUT014. Although the study was not large enough to show statistically significant differences, it demonstrated a trend favoring LUT014, with a shorter recovery time compared to the placebo group.
LUT014 works by utilizing the paradoxical effect of B-Raf inhibitors to promote cell growth in normal cells, which is the opposite of its effect in mutated cells, such as those found in melanoma. Radiation dermatitis is caused by ionizing events from radiation therapy that damage cellular structures, including DNA, and disrupt the skin's protective barrier. Lutris Pharma is dedicated to enhancing the effectiveness of anti-cancer therapies and the quality of life for patients dealing with dermal toxicity from EGFR inhibitors or radiation. The company's lead asset, LUT014, is also undergoing a phase 2 trial for treating acneiform lesions in metastatic colorectal cancer patients.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!